Literature DB >> 12447628

Mortality patterns in childhood lupus--10 years' experience in a developing country.

S Singh1, L Kumar, K Joshi.   

Abstract

Over the last 10 years we have seen 31 children with systemic lupus: 10 (32%) of these have died. The commonest primary determinant of mortality was uncontrolled disease activity (60%), possibly contributed to by late referrals leading to delays in diagnosis and the institution of therapy. Thromboembolic disease was responsible for two deaths and tuberculosis for one. The major contributory factors were nephritis in two patients and myocarditis, endocarditis, lupus pneumonia and CNS disease in one patient each. Concomitant infections, predominantly nosocomial, occurred in a significant proportion of patients (40%) but were only cofactors in mortality. Autopsies were done in three cases. These patterns of death are significantly different from those seen in the developed world, where disease activity has ceased to be an important factor owing to early recognition of cases. Avoiding late referrals and delays in diagnosis can reduce mortality in childhood-onset lupus.

Entities:  

Mesh:

Year:  2002        PMID: 12447628     DOI: 10.1007/s100670200116

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  11 in total

1.  Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa.

Authors:  L B Lewandowski; L E Schanberg; N Thielman; A Phuti; A A Kalla; I Okpechi; P Nourse; P Gajjar; G Faller; P Ambaram; H Reuter; G Spittal; C Scott
Journal:  Lupus       Date:  2016-08-19       Impact factor: 2.911

Review 2.  Prevalence and burden of pediatric-onset systemic lupus erythematosus.

Authors:  Sylvia Kamphuis; Earl D Silverman
Journal:  Nat Rev Rheumatol       Date:  2010-08-03       Impact factor: 20.543

3.  Epidemiology treatment and outcome of childhood systemic lupus erythematosus in Egypt.

Authors:  Ashraf Bakr
Journal:  Pediatr Nephrol       Date:  2005-06-07       Impact factor: 3.714

Review 4.  Management and outcomes in children with lupus nephritis in the developing countries.

Authors:  Priyanka Khandelwal; Srinivasavaradan Govindarajan; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2022-10-18       Impact factor: 3.651

5.  Childhood lupus nephritis: 12 years experience from North India.

Authors:  Surjit Singh; Ranjana Minz; Ritambhra Nada; Kusum Joshi
Journal:  Rheumatol Int       Date:  2006-05       Impact factor: 2.631

6.  Outcome of lupus nephritis in Iranian children: prognostic significance of certain features.

Authors:  Neamatollah Ataei; Manijeh Haydarpour; Abbas Madani; Seyed Taher Esfahani; Niloufar Hajizadeh; Mohammad Hasan Moradinejad; Taghi Gholmohammadi; Shahriar Arbabi; Marzieh Haddadi
Journal:  Pediatr Nephrol       Date:  2008-02-13       Impact factor: 3.714

7.  Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII).

Authors:  L B Tucker; A G Uribe; M Fernández; L M Vilá; G McGwin; M Apte; B J Fessler; H M Bastian; J D Reveille; G S Alarcón
Journal:  Lupus       Date:  2008-04       Impact factor: 2.911

8.  Antiphospholipid antibodies in children with systemic lupus erythematosus: a long-term clinical and laboratory follow-up status study from northwest India.

Authors:  Jasmina Ahluwalia; Surjit Singh; Shano Naseem; Deepti Suri; Amit Rawat; Anju Gupta; Joseph Masih; Sunil Bose
Journal:  Rheumatol Int       Date:  2013-04-07       Impact factor: 2.631

9.  Neuropsychiatric manifestations and antiphospholipid antibodies in pediatric onset lupus: 14 years of experience from a tertiary center of North India.

Authors:  Surjit Singh; Mukesh Kumar Gupta; Jasmina Ahluwalia; Paramjeet Singh; Prahbhjot Malhi
Journal:  Rheumatol Int       Date:  2009-03-22       Impact factor: 2.631

Review 10.  Improving musculoskeletal health for children and young people - A 'call to action'.

Authors:  Helen E Foster; Christiaan Scott; Carl J Tiderius; Matthew B Dobbs
Journal:  Best Pract Res Clin Rheumatol       Date:  2020-07-26       Impact factor: 4.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.